Adjusted odds ratios for subgroup analysis. 
STUDY SELECTION
Studies were considered eligible if they (1) were performed on patients with acute ischemic stroke who were aged 18 years or older, (2) included patients who were treated with tissue plasminogen activator, (3) compared patients receiving prestroke antiplatelet medications with those who were not, and (4) reported at least one of the outcomes defined (symptomatic intracranial hemorrhage, modified Rankin Scale score, and death from all causes). Variations in how outcomes were defined (including definitions of symptomatic intracranial hemorrhage) existed across studies; any reported symptomatic intracranial hemorrhage within 7 days and any modified Rankin Scale score or mortality within 90 days from stroke onset were considered antiplatelet agent as monotherapy or among those receiving aspirin and dipyridamole combination therapy (Table) . 5 Furthermore, the pooled results did not demonstrate an increased risk of poor functional outcome (ie, modified Rankin Scale score) or mortality with any of the prestroke antiplatelet agents or their combinations. Although the systematic review was based on data from more than 100,000 patients, the findings of the meta-analysis were primarily driven by the studies by Xian et al 6 and Diedler et al. 7 These 2 studies accounted for more than 70% of the weighted analysis for the 3 outcomes of symptomatic intracranial hemorrhage, modified Rankin Scale score, and mortality. To put the odds ratios into perspective, the unadjusted rates of symptomatic intracranial hemorrhage in the largest study (ie, by Xian et al 6 ) were low for patients receiving antiplatelet therapy (5.0%) and those not receiving antiplatelet therapy (3.7%).
The studies by Xian et al 6 and Diedler et al 7 showed an increase in symptomatic intracranial hemorrhage with aspirin and clopidogrel combination therapy. However, the chosen definition for symptomatic intracranial hemorrhage varied among the studies. In the one by Xian et al, 6 symptomatic intracranial hemorrhage was defined as hemorrhage within 36 hours in combination with the treating physician's note indicating clinical deterioration attributable to hemorrhage. In their analysis, the prestroke use of aspirin and clopidogrel in combination was associated with an increase in the adjusted odds ratio of symptomatic intracranial hemorrhage (odds ratio 1.47; 95% confidence interval 1.16 to 1.86). The magnitude of effect for symptomatic intracranial hemorrhage with this combination was larger in the study by Diedler 7 In other words, small changes in clinical status that might not have resulted in a change in NIHSS would have been classified as symptomatic intracranial hemorrhage by Xian et al. 6 Furthermore, interpretation of hemorrhage risks is also affected by the timing of outcome measurement within the definitions. The symptomatic intracranial hemorrhage definition by Xian et al 6 
